German Authority Gives Go Ahead To Novo Nordisk's Small Bolt On Acquisition As Danish Firm Seeks To Build Heart Drugs Pipeline
German Authority Gives Go Ahead To Novo Nordisk's Small Bolt On Acquisition As Danish Firm Seeks To Build Heart Drugs Pipeline
Thursday, Germany's competition authority, Bundeskartellamt, cleared the planned acquisition of Cardior Pharmaceuticals GmbH by Danish pharma giant Novo Nordisk A/S (NYSE:NVO).
周四，德国竞争管理机构Bundeskartellamt批准了丹麦制药巨头诺和诺德A/S（纽约证券交易所代码：NVO）收购Cardior Pharmicals GmbH的计划。
Cardior is a biotech company focusing on heart diseases, in the case at hand cardiac insufficiency or heart failure.
Cardior是一家生物技术公司，专注于心脏病，例如心脏功能不全或心力衰竭。
The company has not yet offered any approved substances. Cardior's main development product is an active substance against cardiac insufficiency caused by heart attacks.
该公司尚未提供任何经批准的物质。Cardior的主要开发产品是一种针对心脏病发作引起的心功能不全的活性物质。
In March, Novo Nordisk agreed to acquire Cardior for up to €1.025 billion. The agreement includes Cardior's lead compound, CDR132L, which is currently in phase 2 clinical development for the treatment of heart failure.
3月，诺和诺德同意以高达10.25亿欧元的价格收购Cardior。该协议包括Cardior的主要化合物 CDR132L，该化合物目前处于治疗心力衰竭的第二阶段临床开发阶段。
The acquisition is an important step forward in Novo Nordisk's strategy to establish a presence in cardiovascular disease.
此次收购是诺和诺德在心血管疾病领域建立业务的战略向前迈出的重要一步。
"By welcoming Cardior as a part of Novo Nordisk, we will strengthen our pipeline of projects in cardiovascular disease where we already have ongoing programs across all phases of clinical development," said Martin Holst Lange, executive vice president for Development at Novo Nordisk.
诺和诺德开发执行副总裁马丁·霍尔斯特·兰格表示：“通过欢迎Cardior加入诺和诺德，我们将加强我们在心血管疾病领域的项目渠道，我们已经在临床开发的各个阶段进行了持续的项目。”
CDR132L is designed to halt and partially reverse cellular pathology by selectively blocking abnormal levels of the microRNA molecule miR-132. This could potentially lead to long-lasting improvement in heart function.
CDR132L 旨在通过选择性地阻断 microRNA 分子 miR-132 的异常水平来阻止和部分逆转细胞病理。这有可能导致心脏功能的长期改善。
In a phase 1b trial published in the European Heart Journal, CDR132L was reported to be safe and well tolerated. The results suggested cardiac functional improvements in people with heart failure compared to placebo.
在《欧洲心脏杂志》上发表的一项1b期试验中，据报道，CDR132L 安全且耐受性良好。结果表明，与安慰剂相比，心力衰竭患者的心脏功能有所改善。
CDR132L is currently being investigated in the phase 2 trial HF-REVERT in 280 people with heart failure with reduced ejection fraction (HFrEF) who have previously suffered a heart attack (myocardial infarction). The first patient was dosed in the HF-REVERT trial in July 2022.
HF-REVERT 的 2 期试验目前正在研究 CDR132L，该试验针对 280 名先前曾遭受过心脏病发作（心肌梗塞）的心力衰竭、射血分数降低的心力衰竭（HFref）患者。2022年7月，在HF-REVERT试验中，第一位患者接受了给药。
Novo Nordisk plans to initiate a second phase 2 trial that will investigate CDR132L in a chronic heart failure population with cardiac hypertrophy – a condition characterized by thick and stiff heart muscles.
Novo Nordisk计划启动第二阶段试验，该试验将调查伴有心脏肥大的慢性心力衰竭人群中的 CDR132L，这种疾病的特征是心肌粗壮而僵硬。
The deal is expected to close in the second quarter of 2024.
该交易预计将于2024年第二季度完成。
Price Action: NVO shares are down 1.42% at $122.77 at the last check Thursday.
价格走势：在周四的最后一次检查中，NVO股价下跌1.42％，至122.77美元。
Photo via Shutterstock
照片来自 Shutterstock